Top in cardiology: BP effects of flavonoid-rich foods, expanded indication for Xarelto
Click Here to Manage Email Alerts
Recent data showed that flavonoid-rich foods, such as berries, apples, pears and wine, can positively impact BP. It was the top story in cardiology last week.
Another top story was about the expanded indication for Xarelto (rivaroxaban, Janssen Pharmaceuticals). Patients with lower-extremity revascularization due to symptomatic peripheral artery disease will now be able to take 2.5 mg of rivaroxaban twice daily in conjunction with aspirin.
Read these and more top stories in cardiology below:
Flavonoid-rich foods confer BP benefits, partly explained by gut bacteria
Flavonoid-rich foods appear to have beneficial effects on BP, explained in part by gut microbiome characteristics, researchers reported in Hypertension. Read more.
FDA grants expanded indication for rivaroxaban related to PAD population
Janssen Pharmaceuticals announced that the FDA has granted an expanded indication to rivaroxaban, now allowing it for use in patients who had recent lower-extremity revascularization due to symptomatic peripheral artery disease. Read more.
Empagliflozin becomes first agent to improve outcomes in HFpEF: EMPEROR-Preserved
Anticipated results of the EMPEROR-Preserved trial demonstrate that the SGLT2 inhibitor Jardiance (empagliflozin, Boehringer Ingelheim/Eli Lilly) improved clinical outcomes in patients with HF with preserved ejection fraction — the first agent to be shown to do so. Read more.
LoDoCo2: Colchicine benefits consistent regardless of ACS history, timing
In patients with chronic coronary disease, the beneficial effects of colchicine were consistent regardless of history of ACS and time of treatment following ACS, according to new data from the LoDoCo2 trial. Read more.
Finerenone shows HF benefit in mild to moderate diabetic kidney disease: FIGARO-DKD
The nonsteroidal mineralocorticoid receptor antagonist Kerendia (finerenone, Bayer) reduced cardiovascular event risk by 13% for adults with diabetic kidney disease compared with placebo, primarily driven by a 29% reduction in heart failure hospitalizations. Read more.